Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Diaceutics ( (GB:DXRX) ) just unveiled an update.
Diaceutics PLC announced that Graham Paterson, the Senior Independent Non-Executive Director, purchased 11,643 ordinary shares at 137.5 pence per share, increasing his total shareholding to 85,141 shares, which represents about 0.10% of the company’s issued share capital. This transaction highlights confidence in the company’s market position and strategy, potentially impacting stakeholder perspectives on the company’s future growth and stability.
More about Diaceutics
Diaceutics PLC is a leading technology and solutions provider to the pharma and biotech industry, offering end-to-end commercialization solutions for precision medicines. The company leverages data analytics, scientific and advisory services through its platform, DXRX – The Diagnostics Network, aiming to ensure patients receive appropriate testing and therapies for better disease outcomes.
YTD Price Performance: 24.09%
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $143.7M
See more data about DXRX stock on TipRanks’ Stock Analysis page.
